ELANCO ANIMAL HEALTH

NYSE: ELAN (Elanco Animal Health Incorporat)

最近更新时间: 25 Nov, 2025, 4:56PM

23.43

0.34 (1.47%)

前收盘价格 23.09
收盘价格 23.20
成交量 3,004,630
平均成交量 (3个月) 6,993,890
市值 11,641,511,936
市盈率 (P/E TTM) 334.71
预期市盈率 (P/E Forward) 22.12
价格/销量 (P/S) 2.53
股市价格/股市净资产 (P/B) 1.71
52周波幅
8.02 (-65%) — 23.59 (0%)
利润日期 5 Nov 2025
营业毛利率 8.43%
营业利益率 (TTM) 10.14%
稀释每股收益 (EPS TTM) 0.750
季度收入增长率 (YOY) -1.00%
季度盈利增长率 (YOY) 109.40%
总债务/股东权益 (D/E MRQ) 69.18%
流动比率 (MRQ) 2.71
营业现金流 (OCF TTM) 535.00 M
杠杆自由现金流 (LFCF TTM) 1.32 B
资产报酬率 (ROA TTM) 1.14%
股东权益报酬率 (ROE TTM) 6.01%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 混合的 看涨
Drug Manufacturers - Specialty & Generic (全球的) 混合的 看涨
股票 Elanco Animal Health Incorporat 看涨 看涨

AIStockmoo 评分

-0.5
分析师共识 1.5
内部交易活动 NA
价格波动 -4.5
技术平均移动指标 -1.0
技术振荡指标 2.0
平均 -0.50

相关股票

股票 市值 DY P/E(TTM) P/B
ELAN 12 B - 334.71 1.71
PBH 3 B - 15.83 1.61
ZTS 53 B 0.83% 20.32 10.36
TAK 48 B 4.61% 206.71 1.10
HLN 46 B 1.14% 22.82 2.07
RDY 12 B 54.73% 17.97 2.89

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Core
内部持股比例 1.03%
机构持股比例 101.48%
52周波幅
8.02 (-65%) — 23.59 (0%)
目标价格波幅
22.00 (-6%) — 30.00 (28%)
30.00 (Barclays, 28.04%) 购买
27.00 (15.24%)
22.00 (Morgan Stanley, -6.10%) 保留
平均值 26.50 (13.10%)
总计 3 购买, 1 保留
平均价格@调整类型 21.57
公司 日期 目标价格 调整类型 价格@调整类型
Morgan Stanley 18 Dec 2025 22.00 (-6.10%) 保留 22.09
Barclays 09 Dec 2025 30.00 (28.04%) 购买 20.43
Keybanc 21 Nov 2025 27.00 (15.24%) 购买 22.25
UBS 06 Nov 2025 27.00 (15.24%) 购买 21.52
20 Oct 2025 25.00 (6.70%) 购买 21.72

该时间范围内无数据。

日期 类型 细节
06 Jan 2026 公告 Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
31 Dec 2025 公告 Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
18 Dec 2025 公告 Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
09 Dec 2025 公告 Elanco Investor Day Defines New Era as Sustainable Growth Company
26 Nov 2025 公告 Elanco executive appointed as Neurizon's Board Observer
21 Nov 2025 公告 Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats
20 Nov 2025 公告 Elanco to Participate in the Upcoming Investor Conferences
13 Nov 2025 公告 Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health
05 Nov 2025 公告 Elanco Animal Health Reports Third Quarter 2025 Results
27 Oct 2025 公告 Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
24 Oct 2025 公告 Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
16 Oct 2025 公告 Elanco to Host Investor Day on December 9
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票